Anti-atherosclerotic effect of repaglinide or glimepiride in Japanese type 2 diabetic patients

Anti-atherosclerotic effect of repaglinide or glimepiride in Japanese type 2 diabetic patients - Anti-atherosclerotic effect of repaglinide or glimepiride

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008324

Enrollment

120

Registered

2012-07-07

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Repaglinide0.75mg/day~dose up Glimepiride0.5mg/day~dose up

Sponsors

Fukuoka university, school of medicine, Department of Endocinology and Diebtes Mellitus

Lead Sponsor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes HbA1c(NGSP)6.6%~

Exclusion criteria

Exclusion criteria: type 1 diabetes episode of diabetic ketosis current use of sulfonylure, glinides or insulin

Design outcomes

Primary

Measure	Time frame
HbA1c(NGSP) Cervical IMT serum 8OHdG hsCRP oxidized LDL	—

Countries

Japan

Contacts

Public ContactTakashi Nomiyama

Fukuoka university, school of medicine Endocinology and Diebtes Mellitus

tnomiyama@fukuoka-u.ac.jp092-801-1011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026